Protalix BioTherapeutics Inc. (AMEX:PLX) does about 385.63K shares in volume on a normal day but saw 3291284 shares change hands in Monday trading. The company now has a market cap of 69.92M USD. Its current market price is $1.38, marking a decrease of -17.37% compared to the previous close of $1.67. The 52 week high reached by this stock is $2.00 whilst the lowest price level in 52 weeks is $0.70. The script in recent trading has seen the stock touch a high of $1.60 and a low of $1.32.
Protalix BioTherapeutics Inc. (PLX) has a 20-day trading average at $1.4590 and the current price is -31.00% off the 52-week high compared with 97.14% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.2610 and its 200-day simple moving average is $1.1508. If we look at the stock’s price movements over the week, volatility stands at 7.81%, which decreases to 5.79% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.02 to suggest the stock is neutral.
1 analysts observing the Protalix BioTherapeutics Inc. (PLX) stock have set the 12-month price targets for the company’s shares at between $11.00 and $11.00. The median price target is 87.45% away from the current levels at $11.00.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 08, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $3 and $11. Rodman & Renshaw initiated its price target at $3.50.
The current price level is -5.09%, 10.07%, and 19.87% away from its SMA20, SMA50, and SMA200 respectively, with the PLX price moving below the 50-day SMA on January 23. Protalix BioTherapeutics Inc. (PLX) stock is down -14.81% over the week and 6.15% over the past month. Its price is 0.73% year-to-date and 65.61% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.11 above consensus estimates by $0.07. The company’s next earnings report is expected on 05/10/2023, with forecasts estimating quarterly EPS at -$0.15 and -$0.48 for whole year. PLX’s earnings per share are forecast to grow by 22.60% this year and 133.30% over next year. Expected sales for next quarter are $6.12 million, which analysts say will come at $36.65 million for the current fiscal year and next year at $63.24 million. In addition, estimates put the company’s current quarterly revenue at an average of $5.69 million.
Its 12-month price target is $11.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $11.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $11.00.
Outstanding shares total 50.67M with insiders holding 17.92% of the shares and institutional holders owning 5.27% of the company’s common stock. Price to sales ratio is 1.47.